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Purpose: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen®) injection in the 
management of refractory macular edema secondary to branch retinal vein occlusion.
Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five 
patients with macular edema refractory to either bevacizumab or triamcinolone were treated 
with intravitreal injection of Pegaptanib sodium.
Results: After three months follow-up, both visual acuity and macular edema, measured by 
optical coherence tomography and fluorescence angiography, dramatically improved.
Conclusion: Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary 
to branch retinal vein occlusion.
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Introduction
Branch retinal vein occlusion (BRVO) is a retinal vascular disorder with heterogeneous 
and complex pathophysiology, commonly affecting elderly patients. Macular edema 
associated with BRVO is the most common complication and major cause of visual loss 
in these patients, together with retinal capillary nonperfusion and intraretinal hemor-
rhages. Different therapies have been proposed to treat the macular edema and improve 
the visual prognosis of these patients. One of the first widely accepted treatments was 
the use of a grid pattern laser photocoagulation.1 Although many studies demonstrate 
a statistically significant difference between laser-treated eyes and control-group eyes, 
visual improvement is limited, and some cases are refractory to laser treatment.2
Intravitreal triamcinolone appeared as an alternative treatment to laser. Different 
studies show an important improvement in visual acuity and macular edema follow-
ing intravitreal triamcinolone injection, but its effects are limited by many secondary 
effects and the need of multiple re-injections.3,4 Recently, the results of the dexam-
ethasone implant in patients with macular edema due to retinal vein occlusion have 
been published (GENEVA study); it is concluded that the dexamethasone implant 
improves the speed and incidence of visual improvement in the treated eyes compared 
with the sham-treated group.5
The agents that inhibit the effects of vascular endothelial growth factor (VEGF), 
which is involved in pathophysiology of macular edema,6 have been used, in many cases 
in an off-label manner, to treat a variety of ocular diseases, including macular edema 
secondary to retinal vein occlusion, with satisfactory results. Many studies have found 
analogous anatomical (measured by optical coherence tomography [OCT]) and visual 
acuity responses to bevacizumab and ranibizumab (nonselected anti-VEGF therapies) Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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with limited adverse side effects in branch and central retinal 
vein occlusion.7–9
In this study, we prospectively studied the efficacy of 
intravitreal pegaptanib sodium (Macugen®) by use of OCT 
(Stratus OCT Model 3000, Humphrey Instruments, Carl Zeiss 
Inc, Dublin, CA), fluorescein angiography (FA) and best-
corrected visual acuity (BCVA) in five eyes of five patients 
with refractory macular edema secondary to BRVO, with a 
mean follow-up of 3 months.
Methods
Five eyes of five patients with refractory macular edema 
due to BRVO were enrolled consecutively between May 
and September 2010 for this study. All patients had a visual 
acuity of 0.6 or worse, and the evolution of the macular 
edema was at least 1 year. After the patient signed the cor-
responding informed consent, intravitreal pegaptanib sodium 
0.3 mg/90 µL injection was performed in the operating room. 
Topical anesthetic drops, an antibiotic drop, and povidone 
iodine were administered. Two intravitreal injections of 
pegaptanib sodium were performed in all cases (5 weeks 
apart). Patients were followed up for three months after the 
second injection.
Pre- and post-injection examination included best-
corrected Snellen visual acuity measurement (converted to 
logMAR [logarithm of the minimum angle of resolution]), 
slit-lamp biomicroscopy, Goldmann applanation tonometry, 
fundus examination, OCT, and FA.
Results
Five eyes of five patients were included in the study (two 
men and three women). The mean age of the patients was 
69 (range 63–75); the clinical characteristics of the patients 
included in the study are summarized in Table 1. The macu-
lar edema in all cases had limited or no response to prior 
treatments with either intravitreal triamcinolone acetonide or 
bevacizumab injections. The last treatment before receiving 
the first intravitreal pegaptanib sodium injection was at least 
3 months prior in all cases.
Macular edema reduced from 418 ± 97.7 µm to 
253 ± 97.25 µm, measurable 3 weeks after the first injection 
of pegaptanib sodium by OCT; the FA also demonstrated 
an improvement in macular edema, with complete resolu-
tion of shunts exudation due to the increase in the vascular 
permeability after the retinal vein occlusion (Figure 1). The 
visual acuity improved in all cases by two or more Snellen 
lines. All the findings, visual acuity and resolution of macular 
edema in the OCT, remained stable for 3 months after the 
second injection (Table 1). No side effects associated with 
pegaptanib sodium injection were found in any case.
Discussion
As far as we know, our five patients are the first reported cases 
of refractory macular edema secondary to BRVO treated with 
pegaptanib sodium with excellent results.
Laser and steroid treatment for patients with BRVO 
have had statistically significant benefits in terms of retinal 
thickening and visual acuity, but with several limitations.1,3 
Laser is not useful in cases of macular nonperfusion 
and must be deferred when important hemorrhages are 
present.8 Intravitreal triamcinolone injection had demon-
strated its usefulness in the treatment of macular edema 
due to vascular disorders, but multiple side effects have 
been described associated with it, including cataracts or 
elevated intraocular pressure. In addition, the durability 
of this treatment is not clear, and it is necessary to repeat 
injections.4
Anti-VEGF therapy is useful in the treatment of vascular 
disorders by inactivating the factor involved in the increase 
of vascular permeability that causes macular edema. On the 
other hand, the use of intravitreal bevacizumab for BRVO offers   
significant advantages over triamcinolone and grid-laser   
Table 1 Ophthalmic characteristics of the patients with macular edema secondary to branch retinal vein occlusion treated with 
intravitreal injection of pegaptanib sodium
Patient Age/sex Duration of ME 
(months)
Previous treatment BCVAa before 
PSI
MET before  
PSI
BCVAa after 
PSIb
MET after 
PSIb
1 63/F 12 3 bevacizumab 0.6 418 0.2 236
2 66/F 14 4 bevacizumab 0.7 436 0.2 224
3 75/M 13 2 triamcinolone 0.8 567 0.3 260
4 68/F 16 1 triamcinolone +  
2 bevacizumab
0.6 371 0.1 189
5 72/M 15 3 bevacizumab 0.4 302 0.0 178
Notes: aexpressed in the LogMAr (logarithm of the minimum angle of resolution) scale; bAfter three months follow-up.
Abbreviations: BCVA, best-corrected visual acuity; F, female; M, male; Me, macular edema; MeT, macular edema thickness; Psi, pegaptanib sodium injection.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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treatment, but in our experience and that of several other   
studies, multiple injections are also needed because macular 
edema reappears with the consequential visual loss.10
In another study, 20 patients with macular edema second-
ary to branch vein occlusion were treated with pegaptanib 
sodium injection with satisfactory results up to 54 weeks 
follow-up.11 The main outcome of the study was the efficacy 
of pegaptanib sodium injection in refractory macular edema 
due to branch vein occlusion. The uncontrolled use of nonse-
lective anti-VEGF therapies can worsen visual acuity despite 
the anatomic resolution shown in OCT or FA in the long-
term, because they also block the neuroprotectant isoforms 
of VEGF necessary for the adaptative response of retinal 
neurons to ischemic injury.12 That can be the reason why 
pegaptanib sodium has been effective, where bevacizumab or 
triamcinolone were not; because it has a selective action on 
VEGF165 (main isoform associated with angiogenesis and 
macular edema in ophthalmology) without blocking those 
isoforms necessary for the natural recovery of the retinal 
cells after ischemia.
Pegaptanib sodium should be further evaluated as a treat-
ment option for macular edema associated with BRVO due 
to the excellent results obtained in this study.
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Figure 1 Funduscopy image, fluorescein angiogram, and optical coherence tomography before and after intravitreal injection of pegaptanib sodium (Macugen®). Complete 
resolution of the macular edema secondary to branch retinal vein occlusion can be seen.Clinical Ophthalmology
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